Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Use advanced search instead (articles only)
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Ophthalmology
Vol. 2, Issue 2, 2015
January 20, 2015 EDT
Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
William V. Padula
,
Miguel Cordero-Coma
,
Taygan Yilmaz
,
William V. Padula
,
Michéal J. Gallagher
,
Jonathan D. Campbell
,
autoimmune disease
biologic
uveitis
ophthalmology
cost-minimization analysis
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9895
JHEOR
1.
Padula WV, Cordero-Coma M, Yilmaz T, Padula WV, Gallagher MJ, Campbell JD. Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis.
JHEOR
. 2015;2(2):131-146.
doi:10.36469/9895
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats